Table 4.
Clinical findings, treatment methods and presentation symptoms of the patients hospitalized in the first and the second 6 months
| Clinical findings, treatment methods and presentation symptoms | First 6 months | Last 6 months | P value |
|---|---|---|---|
| n | 403 (46.2%) | 470 (53.8%) | |
| Sex | |||
|
Male (%) Female (%) |
206 (51.1%) 197 (48.9%) |
246 (52.3%) 224 (47.4%) |
0.718 |
| Age, groups, n (%) | |||
|
65–74 75–84 ≥ 85 |
209 (51.9%) 142 (35.2%) 52 (12.9%) |
257 (54.7%) 154 (32.8%) 59 (12.6%) |
0.693 |
| Presence of symptoms, n (%) | |||
|
Fever Cough Fatigue Dsypnea Sputum Headache Loss of taste and smell Myalgia Diarrhea Nausea/vomiting Altered states of consciousness |
91 (22.6%) 113 (28%) 61 (15.1%) 169 (41.9%) 13 (3.2%) 5 (1.2%) 5 (1.2%) 14 (3.5%) 21 (5.2%) 25 (6.2%) 67 (16.6%) |
113 (24.0%) 102 (21.7%) 121 (25.7%) 232 (49.4%) 9 (1.9%) 10 (2.1%) 6 (1.3%) 41 (8.7%) 11 (2.3%) 25 (5.3%) 128 (27.2%) |
0.611 0.030 < 0.001 0.028 0.218 0.315 0.962 0.001 0.024 0.575 < 0.001 |
| Blood pressure on admission, n (%) | |||
|
> 90/60 ≤ 90/60 |
394 (97.8%) 9 (2.2%) |
441 (93.8%) 29 (6.2%) |
0.004 |
| SpO2% on admission, mean ± SD | 92.7 (± 4.7) | 92.4 (± 4.5) | 0.328 |
| The lowest SpO2%, mean ± SD | 88.1 (± 7.8) | 86.5 (± 9.5) | 0.008 |
| COVID PCR positive, n (%) | 190 (47%) | 396 (84%) | < 0.001 |
| Thorax CT Classification, n (%) | |||
|
0 (negative) 1 (atypical) 2 (indeterminate) 3 (typical) |
52 (12.9%) 71 (17.6%) 88 (21.8%) 192 (47.6%) |
38 (8.1%) 68 (14.5%) 62 (13.2%) 302 (64.3%) |
< 0.001 |
| Oxygen treatment, n (%) | 261 (64.8%) | 289 (61.5%) | 0.318 |
| COVID treatment, n (%) | |||
|
Tocilizumab Favipiravir Corticosteroids Anticoagulants |
99 (51.03%) 253 (62.8%) 53 (13.2%) 325 (80.6%) |
95 (48.9%) 405 (86.2%) 299 (63.6%) 441 (93.8%) |
0.238 < 0.001 < 0.001 < 0.001 |
| Patients hospitalized in the intensive care unit | 119 (29.5%) | 177 (37.7%) | 0.011 |
| Death | 88 (21.8%) | 142 (30.2%) | < 0.001 |
Significant P values are in bold